Last reviewed · How we verify
INH preventive therapy
INH preventive therapy is a Antimycobacterial agent Small molecule drug developed by Johns Hopkins University. It is currently FDA-approved for Latent tuberculosis infection (LTBI) prevention in high-risk populations, Prevention of tuberculosis disease progression in tuberculin skin test or interferon-gamma release assay positive individuals.
Isoniazid (INH) preventive therapy inhibits mycobacterial cell wall synthesis by blocking mycolic acid production, preventing the development of active tuberculosis in latently infected individuals.
Isoniazid (INH) preventive therapy inhibits mycobacterial cell wall synthesis by blocking mycolic acid production, preventing the development of active tuberculosis in latently infected individuals. Used for Latent tuberculosis infection (LTBI) prevention in high-risk populations, Prevention of tuberculosis disease progression in tuberculin skin test or interferon-gamma release assay positive individuals.
At a glance
| Generic name | INH preventive therapy |
|---|---|
| Sponsor | Johns Hopkins University |
| Drug class | Antimycobacterial agent |
| Target | InhA (enoyl-ACP reductase) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
INH is a prodrug that is activated by mycobacterial catalase-peroxidase (KatG) to form an INH-NAD adduct, which inhibits InhA, a key enzyme in mycolic acid synthesis. This disrupts the integrity of the mycobacterial cell wall, making it bactericidal. In preventive therapy, INH is administered to individuals with latent tuberculosis infection (LTBI) to prevent progression to active TB disease.
Approved indications
- Latent tuberculosis infection (LTBI) prevention in high-risk populations
- Prevention of tuberculosis disease progression in tuberculin skin test or interferon-gamma release assay positive individuals
Common side effects
- Peripheral neuropathy
- Hepatotoxicity
- Drug-induced lupus
- Hypersensitivity reactions
- Gastrointestinal disturbance
Key clinical trials
- An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM (PHASE3)
- Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency (PHASE3)
- Asymptomatic TB With Innovative Modified Short-course Regimens (PHASE4)
- ThiPhiSA: New Pathways to Prevention From Community TB Screening in South Africa (NA)
- Window Prophylaxis for Pediatric Tuberculosis Prevention Trial (NA)
- Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS) (PHASE1, PHASE2)
- Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients (PHASE4)
- Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- INH preventive therapy CI brief — competitive landscape report
- INH preventive therapy updates RSS · CI watch RSS
- Johns Hopkins University portfolio CI
Frequently asked questions about INH preventive therapy
What is INH preventive therapy?
How does INH preventive therapy work?
What is INH preventive therapy used for?
Who makes INH preventive therapy?
What drug class is INH preventive therapy in?
What development phase is INH preventive therapy in?
What are the side effects of INH preventive therapy?
What does INH preventive therapy target?
Related
- Drug class: All Antimycobacterial agent drugs
- Target: All drugs targeting InhA (enoyl-ACP reductase)
- Manufacturer: Johns Hopkins University — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Latent tuberculosis infection (LTBI) prevention in high-risk populations
- Indication: Drugs for Prevention of tuberculosis disease progression in tuberculin skin test or interferon-gamma release assay positive individuals
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing